Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.

Human immunology - 1 Nov 2014

Arrieta-Bolaños Esteban, Madrigal J Alejandro, Marsh Steven G E, Shaw Bronwen E, Salazar-Sánchez Lizbeth

Abstract excerpt

HLA-B(∗)57:01 is a well-known and cost-effective pharmacogenetic marker for abacavir hypersensitivity. As with other HLA alleles, there is widespread variation in its frequency across populations. The Costa Rica Central Valley Population (CCVP) is the major population in this country. The frequency of HLA-B(∗)57:01 in this population has not been described yet. Thus, our aim was to determine the frequency of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Costa Rica

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dideoxynucleosides

Share to Drug Hypersensitivity

Share to Gene Expression

Share to Heterozygote

Share to HIV Infections

Share to HLA-B Antigens

Source

Identifiers

PMID: 25286002
DOI: 10.1016/j.humimm.2014.09.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.PMID 25286002Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

Prevalence of HLA-B*57:01 and complete linkage disequilibrium with HCP5 rs2395029: Prevalence and DetectionSemantic proximity Read ↗

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.Semantic proximity Read ↗

HLA-B*5701 Allele Prevalence in Treatment-Naïve HIV-Infected Patients from ColombiaSemantic proximity Read ↗

Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.Semantic proximity Read ↗

Prevalence of Human Leukocyte Antigen HLA-B*57:01 in Individuals with HIV in West and Central AfricaSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.Semantic proximity Read ↗

An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe.Semantic proximity Read ↗

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.Semantic proximity Read ↗

HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.Semantic proximity Read ↗

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.